Patents by Inventor Cathy Ritchie

Cathy Ritchie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazo-pyridine derivatives as activin-like receptor kinase (ALK4 or ALK5) inhibitors
    Patent number: 9079897
    Abstract: Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 14, 2015
    Assignee: NOVARTIS AG
    Inventors: Catherine Leblanc, Cathy Ritchie, Duncan Shaw, Nikolaus Johannes Stiefl
  • Inhibitors of phosphatidylinositol 3-kinase
    Patent number: 8404684
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: March 26, 2013
    Assignee: Novartis AG
    Inventors: Ian Bruce, Bernard Cuenoud, Thomas Hugo Keller, Gaynor Elizabeth Pilgrim, Nicola Press, Darren Mark Le Grand, Cathy Ritchie, Barbara Valade, Judy Hayler, Emma Budd
  • Organic compounds
    Patent number: 8367662
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: February 5, 2013
    Assignee: Novartis AG
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
    Publication number: 20110105535
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: January 12, 2011
    Publication date: May 5, 2011
    Inventors: Ian BRUCE, Bernard Cuenoud, Thomas Hugo Keller, Gaynor Elizabeth Pilgrim, Nicola Press, Darren Mark Le Grand, Cathy Ritchie, Barbara Valade, Judy Hayler, Emma Budd
  • Organic Compounds
    Publication number: 20100210641
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Application
    Filed: October 15, 2008
    Publication date: August 19, 2010
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • Heterocyclic compounds as antiinflammatory agents
    Publication number: 20100041662
    Abstract: A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are also useful for treating diseases mediated by the Pi3k receptor, the JAK-2 receptor and the TRK receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: October 29, 2007
    Publication date: February 18, 2010
    Inventors: Sandrine Ferrand, Fraser Glickman, Catherine Leblanc, Cathy Ritchie, Duncan Shaw, Nikolaus Johannes Stiefl, Pascal Furet, Patricia Imbach, Frédéric Stauffer, Hans-Georg Capraro, François Gessier, Christoph Gaul, Pameia A. Albaugh, Greg Chopiuk
  • Inhibitors of phosphatidylinositol 3-kinase
    Publication number: 20070032487
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 8, 2007
    Inventors: Ian Bruce, Bernard Cuenoud, Thomas Keller, Gaynor Pilgrim, Nicola Press, Darren Le Grand, Cathy Ritchie, Barbara Valade, Judy Hayler, Emma Budd